Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

ABSTRACT:

Importance

Optimizing assessments of rate of progression in Parkinson disease (PD) is important in designing clinical trials, especially of potential disease-modifying agents.

Objective

To examine the value of measures of impairment, disability, and quality of life in assessing progression in early PD.

Design, setting, and participants

Inception cohort analysis of data from 413 patients with early, untreated PD who were enrolled in 2 multicenter, randomized, double-blind clinical trials.

Interventions

Participants were randomly assigned to 1 of 5 treatments (67 received creatine, 66 received minocycline, 71 received coenzyme Q10, 71 received GPI-1485, and 138 received placebo). We assessed the association between the rates of change in measures of impairment, d

SUBMITTER: Parashos SA 

PROVIDER: S-EPMC4188544 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature